Mantle Cell Lymphoma

Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Tycel Phillips, MD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Here is your guide to important regulatory approvals made by the FDA in May 2024.

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.